A prior pre-clinical investigation demonstrated that the GLP-1 receptor agonist vildagliptin directly inhibited NF-κB and subsequent pro-inflammatory cytokine cascades in a rotenone rat model of Parkinson’s disease [56]. This evidence concerns the gene GLP1R and Parkinson disease.